Safety of recombinant coagulation factors in treating hemophilia

Introduction: During the last decade, new FVIII/IX concentrates have been developed for the treatment of patients affected by hemophilia A/B. Significant progress has been achieved regarding their half-life, but the old issue of immunogenicity and new concerns about safety need to be addressed. Area...

Full description

Saved in:
Bibliographic details
Volume: 18
Main Author: Morfini, Massimo
Rapisarda, Carlo Antonio Paolo
Format: Journal Article
Language: English
Place of publication: ABINGDON Taylor & Francis 01.02.2019
TAYLOR & FRANCIS LTD
published in: Expert opinion on drug safety Vol. 18; no. 2; pp. 75 - 85
Data of publication: 2/1/2019
ISSN: 1474-0338
1744-764X
EISSN: 1744-764X
Discipline: Public Health
Pharmacy, Therapeutics, & Pharmacology
Subjects:
Online Access: available in Bonn?
Database: Web of Science - Science Citation Index Expanded - 2019
Web of Knowledge
Science Citation Index Expanded
Web of Science
PubMed
CrossRef
MEDLINE - Academic
Database information Databases - DBIS